RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma

Journal of Investigative Dermatology

Volumn 135, Issue 2, 2015, Pages 636-639

  Hassel, Jessica C ^a   Groesser, Leopold ^b   Herschberger, Eva ^b   Weichert, Wilko ^a   Hafner, Christian ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; PROTEIN P21; RAS PROTEIN; B RAF KINASE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ACANTHOLYTIC DYSKERATOSIS; CLINICAL ARTICLE; EPITHELIUM TUMOR; FIBROMA; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MELANOMA; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEBORRHEIC KERATOSIS; VERRUCAL KERATOSIS; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MUTATION; SKIN NEOPLASMS;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); SKIN NEOPLASMS;

EID: 84925348149     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.360     Document Type: Letter

References (22)

1. Anforth R, Tembe V, Blumetti T et al. (2012) Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res 25:569-72
2. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
3. Chu EYC, Wanat KA, Miller CJ et al. (2012) Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 67:1265-72
4. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19
5. Flaherty KT, Robert C, Hersey P et al.METRIC Study Group (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14
6. Ganzenmueller T, Hage E, Yakushko Y et al. (2013) No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients. Exp Dermatol 22:725-9
7. Groesser L, Herschberger E, Ruetten A et al. (2012) Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 44:783-7
8. Groesser L, Herschberger E, Sagrera A et al. (2013) Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. J Invest Dermatol 133:1998-2003
9. Hafner C, Toll A, Gantner S et al. (2012) Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 49:249-53
10. Hafner C, Groesser L (2013) Mosaic RASopathies. Cell Cycle 12:43-50
11. Harvey NT, Millward M, Wood BA (2012) Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol 34:822-6
12. Hauschild A, Grob JJ, Demidov LV et al. (2012) Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-65
13. Holderfield M, Lorenzana E, Weisburd B et al. (2014) Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res 74:2238-45
14. Kazlouskaya V, Shustef E, Allam SH et al. (2013) Expression of p16 protein in lesional and perilesional condyloma acuminata and bowenoid papulosis: clinical significance an diagnostic implications. J Am Acad Dermatol 69:445-9
15. Kulkarni RP, Plaisier S, Ra SH et al. (2013) Genetic profiling of BRAF inhibitor-induced keratoacanthomas reveals no induction of MAP kinase pathway expression. J Invest Dermatol 133:830-2
16. Lu S, Tiekso J, Hietanen S et al. (1999) Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. Acta Derm Venereol 79:268-73
17. Oberholzer PA, Kee D, Dziunycz P et al. (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-21
18. Perez-Sayáns M, Suarez-Penaranda JM, Gayoso-Diz P et al. (2013) The role of P21waf1/CIP1 as a Cip/Kip type cell-cycle regulator in oral squamous cell carcinoma (Review). Med Oral Patol Oral Cir Bucal 18:e219-25
19. Santegoets LA, van Baars R, Terlou A et al. (2012) Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva. Int J Cancer 130:2874-85
20. Sosman JA, Kim KB, Schuchter L et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-14
21. Su F, Viros A, Milagre C et al. (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-15
22. Warfel NA, El-Deiry WS (2013) P21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 25:52-8